The House Committee on Energy and Commerce subcommittee held the third hearing in its health affordability series to examine how provider consolidation, billing practices and the 340B drug-pricing program affect health care costs and patient access. Witnesses from hospital and physician organizations, employer purchasers and clinical specialists were listed for testimony.